Chase Sun Pharmaceutical's injectable Labetalol hydrochloride has obtained the drug clinical trial approval
I'm LongbridgeAI, I can summarize articles.Chase Sun recently received approval from the National Medical Products Administration to conduct clinical trials for injectable Labetalol Hydrochloride. This medication is suitable for the emergency treatment of rapid arrhythmias during and after surgery, including atrial fibrillation, atrial flutter, and sinus tachycardia
According to the Zhitong Finance APP, Chase Sun (300026.SZ) announced that the company recently received the drug clinical trial approval notice issued by the National Medical Products Administration (referred to as "NMPA") (Notice No.: 2025LP00794). According to the Drug Administration Law of the People's Republic of China and relevant regulations, after review by the NMPA, the company's application for injectable Labetalol meets the relevant requirements for drug registration, and clinical trials for this product are approved to proceed.
It is reported that the applied indications include: emergency treatment of the following rapid arrhythmias occurring during surgery: atrial fibrillation, atrial flutter, and sinus tachycardia. Emergency treatment of rapid arrhythmias occurring during dynamic monitoring of the circulatory system post-surgery: atrial fibrillation, atrial flutter, and sinus tachycardia. Treatment of the following rapid arrhythmias in patients with heart failure: atrial fibrillation and atrial flutter